

## Akebia Therapeutics to Report Second Quarter Financial Results and Discuss Recent Business Highlights

August 23, 2023

Akebia to Host Conference Call on August 25th at 9:00 a.m. ET

CAMBRIDGE, Mass., Aug. 23, 2023 /PRNewswire/ -- Akebia Therapeutics. Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the second quarter ended June 30, 2023 on Friday, August 25, 2023.

-

Akebia will host a conference call on Friday, August 25, 2023 at 9:00 a.m. ET to discuss its financial results and recent business highlights. To access the call by phone, please click on this Registration Link, and you will be provided with dial in details. To avoid delays, we encourage dialing into the conference call fifteen minutes ahead of the scheduled start time.

A live webcast of the conference call will be available via the Investors section of Akebia's website at: <a href="https://ir.akebia.com/">https://ir.akebia.com/</a>. An online archive of the webcast can be accessed via the Investors section of Akebia's website at <a href="https://ir.akebia.com/">https://ir.akebia.com/</a>.

## **About Akebia Therapeutics**

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at <a href="https://www.akebia.com">www.akebia.com</a>, which does not form a part of this release.

## **Akebia Therapeutics Contact**

Mercedes Carrasco mcarrasco@akebia.com

C View original content to download multimedia: <a href="https://www.prnewswire.com/news-releases/akebia-therapeutics-to-report-second-quarter-financial-results-and-discuss-recent-business-highlights-301908497.html">https://www.prnewswire.com/news-releases/akebia-therapeutics-to-report-second-quarter-financial-results-and-discuss-recent-business-highlights-301908497.html</a>

SOURCE Akebia Therapeutics